Venous Thromboembolism and Gender-Affirming Hormone Therapy: A Reappraisal of Risks and Benefits

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Access to Document

@article{3edc547157a348bab165a7c02b3b869a,

title = "Venous Thromboembolism and Gender-Affirming Hormone Therapy: A Reappraisal of Risks and Benefits",

keywords = "gender-affirming hormone therapy, venous thromboembolism",

author = "Dreijerink, {Koen M. A.}",

year = "2023",

month = apr,

doi = "10.1016/j.eprac.2022.12.010",

language = "English",

volume = "29",

pages = "301--302",

journal = "Endocrine Practice",

issn = "1530-891X",

publisher = "American Association of Clinical Endocrinology",

number = "4",

}

TY - JOUR

T1 - Venous Thromboembolism and Gender-Affirming Hormone Therapy

T2 - A Reappraisal of Risks and Benefits

AU - Dreijerink, Koen M. A.

PY - 2023/4

Y1 - 2023/4

KW - gender-affirming hormone therapy

KW - venous thromboembolism

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150378668&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/36871832

U2 - 10.1016/j.eprac.2022.12.010

DO - 10.1016/j.eprac.2022.12.010

M3 - Comment/Letter to the editor

C2 - 36871832

SN - 1530-891X

VL - 29

SP - 301

EP - 302

JO - Endocrine Practice

JF - Endocrine Practice

IS - 4

ER -